Noninvasive Prediction of Congenital Cytomegalovirus Infection After Maternal Primary Infection.

ABSTRACT:

Objective

To develop and internally validate a noninvasive method for the prediction of congenital cytomegalovirus (CMV) infection after primary maternal CMV infection.

Methods

We conducted a secondary analysis of a multicenter randomized placebo-controlled trial of CMV hyperimmune globulin to prevent congenital infection. Women were eligible if they had primary CMV infection, defined as detectable plasma CMV-specific immunoglobulin (Ig)M and CMV-specific IgG with avidity less than 50% before 24 weeks of gestation or IgG seroconversion before 28 weeks, and were carrying a singleton fetus without ultrasonographic findings suggestive of CMV infection. Antibody assays were performed in a single reference laboratory. Congenital infection was defined as CMV detection in amniotic

SUBMITTER: Rouse DJ 

PROVIDER: S-EPMC8857032 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature